Ultrasound/Elastography techniques, lipidomic and blood markers compared to Magnetic Resonance Imaging in non-alcoholic fatty liver disease adults.

CONCLUSIONS: A panel combination including routine blood markers linked to insulin resistance showed highest associations with MRI considered as a gold standard for determining liver fat content. This combination of tests can facilitate the diagnosis of early stages of non-alcoholic liver disease thereby avoiding other invasive and expensive methods. PMID: 30662331 [PubMed - in process]
Source: International Journal of Medical Sciences - Category: Biomedical Science Tags: Int J Med Sci Source Type: research

Related Links:

Non-alcoholic fatty liver disease (NAFLD) has emerged as one of the leading liver diseases worldwide. NAFLD is characterised by hepatic steatosis and may progress to an inflammatory condition termed non-alcoholic steatohepatitis, (NASH), liver cirrhosis and hepatocellular carcinoma. It became evident in the last years that NAFLD pathophysiology is complex and involves diverse immunological and metabolic pathways. An association between intestinal signals (e.g. derived from the gut microbiota) and the development of obesity and its metabolic consequences such as NAFLD are increasingly recognized. Preclinical studies have sh...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
Publication date: Available online 3 September 2019Source: Redox BiologyAuthor(s): Mi Hye Kim, Jung Bae Seong, Jae-Won Huh, Yong Chul Bae, Hyun-Shik Lee, Dong-Seok LeeAbstractNon-alcoholic fatty liver disease (NAFLD) is becoming the most common chronic liver disease globally. NAFLD—which can develop into liver fibrosis, nonalcoholic steatohepatosis, cirrhosis, and hepatocellular carcinoma—is defined as an excess accumulation of fat caused by abnormal lipid metabolism and excessive reactive oxygen species (ROS) generation in hepatocytes. Recently, we reported that Peroxiredoxin 5 (Prx5) plays an essential role i...
Source: Redox Biology - Category: Biology Source Type: research
Fatty liver disease is characterized by a series of pathological conditions ranging from hepatic lipid accumulation (steatosis), to hepatocyte degeneration (ballooning), inflammation (steatohepatitis) and, eventually, cirrhosis and hepatocellular carcinoma [1,2]. Fatty liver disease may be the result of long-term excessive ethanol consumption, (alcoholic liver disease), or of visceral obesity and metabolic syndrome without ethanol consumption, leading to nonalcoholic fatty liver disease (NAFLD) which can evolve to nonalcoholic steatohepatitis (NASH) [3].
Source: Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research
The prevalence of non-alcoholic fatty liver disease (NAFLD) has been increasing rapidly and at the forefront of worldwide concern. Characterized by excessive fat accumulation in the liver, NAFLD regularly coexists with metabolic disorders, including type 2 diabetes, obesity, and cardiovascular disease. It has been well established that the presence of NAFLD increases the incidence of type 2 diabetes, while diabetes aggravates NAFLD to more severe forms of steatohepatitis, cirrhosis, and hepatocellular carcinoma. However, recent progress on the genotype/phenotype relationships in NAFLD patients indicates the development of ...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
The recent epidemic of chronic liver disease is related to the burden of non-alcoholic fatty liver disease (NAFLD), paralleling the worldwide increase of obesity.1 NAFLD is a complex condition related to metabolic derangements in insulin resistance (IR), but in a subset of patients the liver becomes the target of multiple hits leading to non-alcoholic steatohepatitis (NASH), the histological phenotype that may progressively lead to the development of liver fibrosis, cirrhosis and possibly hepatocellular carcinoma.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research
The recent epidemic in chronic liver disease is related to the burden of Non-Alcoholic Fatty Liver Disease (NAFLD), paralleling the worldwide increase of obesity. [1] NAFLD is a complex condition related to metabolic derangements in insulin resistance (IR), but in a subset of patients the liver becomes the target of multiple hits leading to Non-Alcoholic SteatoHepatitis (NASH), the histological phenotype that may progressively develop liver fibrosis, cirrhosis and possibly hepatocellular carcinoma.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research
[Microbiome &NASH - partners in crime driving progression of fatty liver disease]. Z Gastroenterol. 2019 Jul;57(7):871-882 Authors: Wree A, Geisler LJ, Tacke F Abstract Along with the increasing prevalence of obesity, metabolic syndrome and type 2 diabetes, non-alcoholic fatty liver disease (NAFLD) is rapidly increasing and poses a major challenge for gastroenterologists. Many studies have demonstrated that the microbiome is closely associated with the progression of nutrition-related diseases, especially of fatty liver disease. Changes in the quantity and quality of the intestinal flora, commonly...
Source: Zeitschrift fur Gastroenterologie - Category: Gastroenterology Authors: Tags: Z Gastroenterol Source Type: research
Abstract Non-alcoholic fatty liver disease (NAFLD) is histologically classified as either non-alcoholic fatty liver or non-alcoholic steatohepatitis (NASH). NASH is the progressive subtype of NAFLD. Individuals with NASH are at significant risk of developing hepatic fibrosis, cirrhosis, hepatocellular carcinoma, and liver-related and all-cause mortality. NAFLD is closely associated with obesity, type 2 diabetes mellitus (T2DM), metabolic syndrome, and cardiovascular events. Its prevalence is estimated to be above 30% in Turkey; and recent studies confirm this estimate. According to these studies, the prevalence of...
Source: The Turkish Journal of Gastroenterology - Category: Gastroenterology Authors: Tags: Turk J Gastroenterol Source Type: research
Abstract Nonalcoholic fatty liver disease (NAFLD) is a heterogeneous and complex disease that is imprecisely diagnosed by liver biopsy. NAFLD covers a spectrum that ranges from simple steatosis, nonalcoholic steatohepatitis (NASH) with varying degrees of fibrosis, to cirrhosis, which is a major risk factor for hepatocellular carcinoma. Lifestyle and eating habit changes during the last century have made NAFLD the most common liver disease linked to obesity, type 2 diabetes mellitus and dyslipidemia, with a global prevalence of 25%. NAFLD arises when the uptake of fatty acids (FA) and triglycerides (TG) from circul...
Source: World Journal of Gastroenterology : WJG - Category: Gastroenterology Authors: Tags: World J Gastroenterol Source Type: research
This study aims to determine the effect of type 2 diabetes mellitus and insulin therapy on non-alcoholic fatty liver disease in the patients with morbid obesity. MATERIAL AND METHODS: Clinical, anthropometric and laboratory data were analyzed together with intraoperative liver biopsies from morbidly obese patients undergoing bariatric surgery. RESULTS: 219 patients with morbid obesity were evaluated. Systemic arterial hypertension (55.9% vs. 33.8%, p = 0.004) and dyslipidemia (67.1% vs. 39.0%, p
Source: Annals of Hepatology - Category: Gastroenterology Tags: Ann Hepatol Source Type: research
More News: Alcoholism | Biomedical Science | Cancer & Oncology | Carcinoma | Cirrhosis | Eating Disorders & Weight Management | Fatty Liver Disease (FLD) | Hepatocellular Carcinoma | Insulin | Liver | Liver Cancer | Liver Disease | MRI Scan | Non-alcoholic Fatty Liver Diseases (NAFLD) | Obesity | Study | Ultrasound | Urology & Nephrology